Abstract: Despite newly developed antiepileptic drugs to suppress epileptic symptoms, approximately one third of patients remain drug refractory. Consequently, there is an urgent need to develop more effective therapeutic approaches to treat epilepsy. A great deal of evidence suggests that endogenous nucleosides, such as adenosine (Ado), guanosine (Guo), inosine (Ino) and uridine (Urd), participate in the regulation of pathomechanisms of epilepsy. Adenosine and its analogues, together with non-adenosine (non-Ado) nucleosides (e.g., Guo, Ino and Urd), have shown antiseizure activity. Adenosine kinase (ADK) inhibitors, Ado uptake inhibitors and Ado-releasing implants also have beneficial effects on epileptic seizures. These results suggest that nucleosides and their analogues, in addition to other modulators of the nucleoside system, could provide a new opportunity for the treatment of different types of epilepsies. Therefore, the aim of this review article is to summarize our present knowledge about the nucleoside system as a promising target in the treatment of epilepsy.
INTRODUCTION
Epilepsy is a neurological disorder characterized by chronically recurrent seizures [1] [2] [3] . It may also be associated with neurobehavioral comorbidities (e.g., impaired cognitive functions, abnormal social behavior and increased risk of psychiatric disorders) [4] . Various types of brain illnesses, such as central nervous system (CNS) infections, traumatic brain injury, stroke and febrile seizures, can induce processes that may lead to the generation of an epileptic brain (epileptogenesis) [3] . As one of the cellular mechanisms of epileptogenesis [3] , the excessive discharge of highly synchronized and hyperexcitable neurons in different brain areas, including the cerebral cortex, hippocampus and several subcortical structures, may induce different types of epileptic seizures [5] [6] [7] . Excessive excitatory neurotransmission (e.g., via the glutamatergic system) and/or a decrease in inhibitory neurotransmission (e.g., via the GABAergic system) may disrupt the excitatory/inhibitory balance, which may excite or exacerbate epileptic seizures [5] [6] [7] [8] .
Approximately 50 million people suffer from epilepsy worldwide and approximately 30% of patients are drug refractory [9] . This refractory state is possibly due to seizureinduced adaptive mechanisms, such as overexpression of the P-glycoprotein and the multidrug-resistance-associated protein [10] [11] [12] . Although the pathomechanisms (mechanisms of pathological processes) of different types of epilepsies *Address correspondence to this author at the Department of Zoology, University of West Hungary, Savaria Campus, Szombathely, Károlyi Gáspár tér 4., 9700 Hungary; Tel: 0036 94/504 409; Fax: 0036 94/504 404; E-mail: zskovacs@ttk.nyme.hu have been elucidated [1] [2] [3] [4] [5] [6] [7] [13] [14] [15] [16] [17] [18] , epilepsy treatment is mainly based on the suppression of symptoms by antiepileptic drugs [19, 20] , which have severe adverse effects [21, 22] . Consequently, there is an urgent need to develop new therapeutic approaches to find safer and more effective antiepileptic strategies to prevent and cure epilepsy.
Nucleosides, such as adenosine (Ado), guanosine (Guo), inosine (Ino) and uridine (Urd), participate in the synthesis of DNA and RNA and are involved in gene transcription, the storage and conversion of energy and the regulation of physiological and pathophysiological processes in the brain (e.g., sleep, memory, Parkinson's disease, psychiatric disorders and epilepsy) [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . In addition, genetic disorders of purine or pyrimidine metabolism may be associated with different diseases [35] [36] [37] [38] . De novo synthesis of nucleosides is limited in the adult brain [39] . Therefore, nucleoside transport into the brain via the blood-brain barrier and a salvage mechanism supply brain cells with nucleosides [40, 41] . The nucleosides may be metabolized intracellularly or extracellularly ( Fig. 1) [40] [41] [42] and transported via the nucleoside transporters expressed in brain cells (Table 1) [40, 41, 43] . There is considerable evidence for neuromodulatory functions of nucleosides. Adenosine and Guo can be released from synaptosomes [44] [45] [46] [47] [48] [49] and may then bind to their specific receptors [32, 50, 51] ; thus, Ado, Guo and most likely Urd [52] may be signaling molecules (neuromodulators or neurotransmitters) in the brain. Area-, age-and genderdependence of nucleoside levels and/or nucleoside metabolism, nucleoside transporters and nucleoside receptors in the brain have been described previously, suggesting that nucleosides have different physiological and pathophysiological Fig. (1) . Pathways of nucleoside metabolism, nucleoside transport and signal transduction mechanisms of nucleoside receptors. Abbreviations: I: nucleoside transporters; II: ATP channels and transporters; 1: nucleoside mono-and diphosphate kinases and nucleoside di-and triphosphate phosphatases; 2: GMPR, GMP reductase; 3: GMPS, GMP synthetase; 4: IMPDH, IMP dehydrogenase; 5: AMPDA, AMP deaminase; 6: ASL, adenylosuccinate lyase; 7: ASS, adenylosuccinate synthetase; 8: UCK, uridine-cytidine kinase; 9: 5'NT, 5'-nucleotidase (cN); 10: ADK, adenosine kinase; 11: UP, uridine phosphorylase; 12: PNP, purine nucleoside phosphorylase; 13: GDA, guanine deaminase; 14: XO, xanthine oxidase; 15: ADA, adenosine deaminase; 16: MTAP, 5'-deoxy-5'-methylthioadenosine phosphorylase; 17: SAHH, adenosylhomocysteinase; 18: HGPRT, hypoxanthine phosphoribosyltransferase (hypoxanthine-guanine phosphoribosyltransferase); 19: APRT, adenine phosphoribosyltransferase; 20: ecto-ATPase; 21: ecto-ADPase; 22: ecto-5'NT, ecto-5'-nucleotidase (eN); 23: ecto-ADA, ectoadenosine deaminase; 24: DPD, dihydropyrimidine dehydrogenase; A 1 , A 2A , A 2B and A 3 : different subtypes of adenosine receptors; Ade: adenine; Ado: adenosine; ADP, adenosine diphosphate; AMP: adenosine monophosphate; ATP: adenosine triphosphate; DHU: dihydrouracil; G i, G 0, G s, G q, G olf : G-proteins (G i : inhibitory, G s : stimulatory and so on); GMP: guanosine monophosphate; Gn: guanine; GTP: guanosine triphosphate; Guo: guanosine; GuoR: Guo receptor; Hyp: hypoxanthine; IMP: inosine monophosphate; Ino: inosine; MTA: 5'-deoxy-5'-methylthioadenosine; SAH: S-adenosylhomocysteine; UA: uric acid; UMP: uridine monophosphate; Ura: uracil; Urd: uridine; UrdR: Urd receptor; UTP: uridine triphosphate; Xn: xanthine.
roles in different brain areas and that these roles may be modulated by age and gender [30, 31, [53] [54] [55] [56] [57] . Among their diverse neuromodulatory functions, nucleosides may have a role in the modulation of epileptic activity as well [27, 33, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] . Therefore, drugs or nucleoside derivatives effective on nucleoside uptake, nucleoside receptors or nucleoside metabolism may be useful for the treatment of different diseases in the CNS, such as epilepsy [31] . Adenosine kinase (ADK) inhibitors, Ado uptake inhibitors and Ado-releasing implants have also been shown to be effective in treating epileptic seizures [27, 32, 65, 67] . In addition, not only Ado but also non-Ado nucleosides (e.g., Guo, Ino and Urd) showed antiseizure/anticonvulsant activity in various epilepsy models and are potential candidates involved in Cyt: cytosine; DAG: diacylglycerol; ENT1/ENT2/ENT3/ENT4 transporters: ENT1/ENT2/ENT3/ENT4 subtype of equilibrative nucleoside transporters; "ei": equilibrative, NBTI (S-(4-nitrobenzyl)-6-thioinosine) insensitive type of ENTs; "es": equilibrative, NBTI sensitive type of ENTs; Gi, G0, Gs, Gq, Golf: G-proteins; GIRK: G-protein-dependent inwardly rectifying K + channels; Guo: guanosine; IP3: inositol 1,4,5-triphosphate; PLC: phospholipase C; Urd: uridine epilepsy [58, [60] [61] [62] [63] [64] 70] . In this review, we summarize what is known about the nucleoside system in the brain in relation to its potential application against epileptic seizures.
THE NUCLEOSIDE SYSTEM IN THE BRAIN
The metabolism of nucleosides is well understood in the brain [30, 41, [71] [72] [73] [74] [75] [76] [77] . Purines and pyrimidines are synthesized (de novo) from precursor molecules such as carbon dioxide, aspartate, 5-phosphoribosyl-1-pyrophosphate (PRPP), glutamine, glycine and formyl groups, as well as from aspartate and carbamyl-phosphate. Purine and pyrimidine bases connect to a D-ribose in ribonucleosides or to a 2-deoxy-D-ribose in deoxyribonucleosides [78] [79] [80] .
The catabolism of nucleotides may occur through several different routes in the brain [30, 40, 41, 72] . Adenosine triphosphate (ATP), Urd triphosphate (UTP) and Guo triphosphate (GTP) are degraded to their corresponding monophosphates, namely, Ado monophosphate (AMP), Urd monophosphate (UMP) and Guo monophosphate (GMP), respectively, by nucleoside di-and triphosphate phosphatases ( Fig. 1) . Metabolism of AMP can lead to the production of Ado or Ino monophosphate (IMP), whereas GMP may degrade to Guo and IMP. The synthesis of Ado from Sadenosylhomocysteine (SAH) by adenosylhomocysteinase (SAHH, S-adenosylhomocysteine hydrolase) has also been demonstrated [81] . Additionally, GMP IMP, IMP GMP, AMP IMP and IMP AMP conversions have been demonstrated in the CNS. The converting enzymes are as follows: cytoplasmic 5'-nucleotidase (5'NT, cN), GMP reductase (GMPR), GMP synthetase (GMPS), IMP dehydrogenase (IMPDH), AMP deaminase (AMPDA), adenylosuccinate lyase (ASL) and adenylosuccinate synthetase (ASS) (Fig. 1) . 5'-Nucleotidase also metabolizes UMP to Urd. The degradation pathway of Ado and Guo can lead to uric acid (UA) via Ino, hypoxanthine (Hyp), xanthine (Xn) (Fig. 1) and via guanine (Gn) and Xn ( Fig. 1) by purine nucleoside phosphorylase (PNP), Gn deaminase (GDA), Xn oxidase (XO) and Ado deaminase (ADA) [41, 71, 73, 74] .
Urd may be metabolized to dihydrouracil (DHU) via uracil (Ura) by dihydropyrimidine dehydrogenase (DPD) and Urd phosphorylase (UP). The extracellular (EC) level of Ado is maintained and regulated by ecto-5'-nucleotidase (ecto-5'NT, eN, e5'NT), ecto-Ado kinase (ecto-ADK) and ectoAdo deaminase (ecto-ADA) [72, 75, 76] (Fig. 1) . The intracellular (IC) salvage mechanism maintains the synthesis of ribo-and deoxyribonucleotides by preserving the purine and pyrimidine nucleosides and their bases. For instance, Hyp and Gn may be converted to IMP and GMP by Hyp phosphoribosyltransferase (HGPRT; hypoxanthine-guanine phosphoribosyltransferase) (Fig. 1) , whereas Ado, adenine (Ade) and Urd are converted to AMP and UMP by ADK, Ade phosphoribosyltransferase (APRT) and Urd-cytidine (Cyd) kinase (UCK), respectively [30, 77] .
Nucleosides are released from brain cells by reverse transport through specific transporters at the cell membrane [43] (Table 1 ). All six (N1-N6) concentrative nucleoside transporters (CNT transporters), which are sodiumdependent and unidirectional, are present in the CNS. Expression of equilibrative nucleoside transporters (ENT1-ENT4; bidirectional by facilitated diffusion) ( Table 1) has also been demonstrated in the brain [30, 43, 82] . The S-(4-nitrobenzyl)-6-thioinosine (NBTI) sensitive ENTs ("es") are inhibited by low levels of NBTI (on the order of nM concentrations), whereas NBTI insensitive ENTs ("ei") are inhibited by higher concentrations of NBTI (on the order of M). Nucleoside base transporters are also detected in the brain [30, 43, 82] .
Expression of G-protein-coupled Ado receptor subtypes (G i and G 0 or Gq: A 1 and A 3 receptor; G s and G olf or G q : A 2A , A 2B receptor) has been detected in the CNS [30, 32] . Signaling mechanisms activated by Ado receptors [32] are summarized in (Fig. 1 and Table 1 ). In addition, a great deal of evidence suggests that both Urd [83, 84] and Guo [50, 51] may bind to their selective receptors, most likely the G-proteincoupled receptors UrdR and GuoR, in the CNS (Fig. 1). 
MODULATORY ROLE OF NUCLEOSIDES ON EPILEPTIC ACTIVITY
The modulatory role of Ado in different brain diseases involving epilepsy has been investigated extensively [31, 32, [85] [86] [87] , and some of the drugs that have effects on the adenosinergic system (e.g., ADK inhibitors) may also be used in the treatment of epileptic seizures [32, 86] . However, nonAdo nucleosides, such as Guo, Ino and Urd, may also decrease the EC level of the excitatory neurotransmitter glutamate and/or increase GABAergic inhibition [88] [89] [90] and participate in pathophysiological processes of epilepsy [58] [59] [60] [61] [62] [63] [64] . Consequently, not only Ado [27, 33, [65] [66] [67] but also nonAdo nucleosides (e.g., Ino, Guo and Urd) and their derivatives may be potential drugs in the treatment of different types of epilepsies. Therefore, in this review, we focused on the effects of Ado, Ino, Guo and Urd on epileptic activity.
Adenosine
Adenosine, a neuromodulator agent, is the primary inhibitor of neuronal activity. Consequently, it may serve as an endogenous anticonvulsant molecule. Its inhibitory action is mainly exerted by A 1 receptors, although A 2A receptors may also be involved in different epilepsy models [91] [92] [93] [94] [95] [96] (Table  3) . A 1 receptor expression has been observed both presynaptically and postsynaptically. Presynaptic receptors decrease the release of neurotransmitters, whereas they stabilize the membrane potential postsynaptically [97] [98] [99] [100] . It is likely that G i/0 proteins are involved in these actions [99, 101] . It has also been demonstrated in the hippocampus that glutamate increases the Ado level via NMDA receptor activation, which may inhibit glutamate release presynaptically via A 1 receptors [102] . The inhibition by Ado may be sufficient (i) to regulate the spreading of seizures, (ii) to decrease epileptic activity ( Table 3 ) and (iii) for seizure termination [96, 101, [103] [104] [105] [106] [107] [108] . An increase in the Ado level in epileptic brain tissue has been demonstrated [109] [110] [111] [112] . Consequently, increasing the Ado level in the brain by specific inhibitors of nucleoside metabolic enzymes (e.g., ADA and ADK inhibitors) and nucleoside transporters ( Table 2 ; Fig. 2A and 2B) , or by Ado-releasing grafts (in which Ado metabolizing enzymes are inactivated) ( Table 4) , ketogenic diets or direct (focal) infusion of Ado (Table 4 ) may have seizurepreventing/decreasing effects [110, [113] [114] [115] [116] [117] [118] [119] [120] [121] . Ketamine-induced (intraperitoneal injection) epileptiform activity Decreased epileptiform activity [217] Kindling (rat amygdala) model Seizure suppression [213] Theophylline-induced (intravenous application) seizures Proconvulsant effect [224] Papaverine Bicuculline-induced (rat prepiriform cortex) seizures Anticonvulsant effect [134] Soluflazine Mg 2+ -free condition, electrically-induced (guineapig hippocampal slices) epileptiform activity Decreased epileptiform activity [218] Abbreviations: ADA: adenosine deaminase; ADK: adenosine kinase; BW534U87: 
Ado Receptor Agonists
Kainic acid-induced (rat prepiriform cortex) seizures Anticonvulsant effect [214] Kindling (rat amygdala, caudate nucleus) model Seizure reduction [119, 272] Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats Seizure reduction [256] Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Bicuculline-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform activity [168] Bicuculline 
Kindling (rat amygdala, and hippocampus) model Seizure suppression, seizure prevention [115, 116, 213, [258] [259] [260] Pilocarpine-induced (intraperitoneal injection) seizures in rats Blocked seizure appearance [258, 261] Pilocarpine-induced (hippocampus) seizures in rats Seizure protection [262] Lithium-pilocarpine-induced status epilepticus in rats Protective effect [216] Pentylenetetrazole-induced (intravenous application) seizures in rats Increased seizure threshold [265] Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats Partial seizure protection [204] Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Pentylenetetrazole-induced seizures in rats Suppressed/abolished tonic phase of generalized tonicclonic seizures [255] Kainic acid-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Electroshock-induced seizures in rats Protective effect [263] Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Bicuculline-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform activity [168] 3-mercaptopropionic acid-induced (intraperitoneal injection) seizures in mice
Increased seizure latency [118] 3-nitropropionic acid-induced (intraperitoneal injection) seizures in mice Anticonvulsant effect [266] 2-CLA (A1 receptor agonist) Mg 2+ -free condition-induced (human neocortical slices) epileptiform activity Decreased/blocked epileptiform activity [219] Kindling (rat piriform cortex, hippocampus, and amygdala) model Anticonvulsant effect [273] [274] [275] [276] [277] Lithium-pilocarpine-induced status epilepticus in rats Protective effect [216] Pentylenetetrazole-induced (subcutane, and intraperitoneal injection) seizures in mice Protective effect [237] Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Pentylenetetrazole-induced (intravenous application) seizures in rats Increased seizure threshold [265] Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Bicuculline-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform activity [168] Kainic acid-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] 3-mercaptopropionic acid-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] CHA (A1 receptor agonist)
Electrical stimulation rat models of status epilepticus Seizure suppression [257] Maximal electroshock (MES; ear-clip electrodes)-induced seizures in mice Increased electroconvulsive threshold [285] Kainic acid-induced (hippocampus) seizures in mice Seizure suppression [92] Genetically epilepsy-prone rat (GEPR-9 strain; activation of seizures by auditory stimulus)
Seizure suppression [94] CCPA (A1 receptor agonist)
Pilocarpine-induced (hippocampus) seizures in rats Seizure protection [253] ( 
Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats and in mice Seizure reduction, anticonvulsant effect [254, 256] Pentylenetetrazole-induced seizures in rats Suppressed/abolished tonic phase of generalized tonicclonic seizures [255] Bicuculline-induced (intraperitoneal injection) seizures in mice Anticonvulsant effect [254] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Seizure prevention [95] PPS (perforant path stimulation) rat model of status epilepticus Decreased progression from self-terminating seizures to selfsustaining status epilepticus (SSSE) and decreased severity of SSSE [68] Kainic acid-induced (intraperitoneal injection) seizures in rats Delayed status epilepticus presentation [235] 4-aminopyridine-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform bursting duration [269] 3-mercaptopropionic acid-induced seizures Increased seizure latency [271] Aminophylline-induced (intraperitoneal application) seizures in mice Delayed time to onset of clonic convulsions [279] Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Electrical stimulation rat models of status epilepticus Seizure suppression [257] CPA (A1 receptor agonist)
Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats Seizure protection [204] Pentylenetetrazole-induced (intravenous application) seizures in rats Increased seizure threshold
Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Penicillin-induced (rabbit cortex) epileptiform activity Prevents the spreading of the epileptic activity [106] Potassium-induced (rat hippocampal slices) epileptiform activity Blocked epileptiform bursting [280] Bicuculline-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform activity [168] Kindling (rat amygdala, hippocampus, caudate nucleus) model Seizure reduction [119, 272] Pilocarpine-induced seizures in rats Anticonvulsant effect [270] 3-mercaptopropionic acid-induced (intraperitoneal injection) seizures in mice
Increased seizure latency [118] Kainic acid-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Pentylenetetrazole-induced (intravenous application) seizures in rats Increased seizure threshold [265] L-PIA (A1 receptor agonist)
Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice
Increased seizure latency [118] Pilocarpine-induced (intraperitoneal injection) seizures in rats Reduced seizure occurrence [268] Pilocarpine-induced (intraperitoneal injection) seizures in rats Anticonvulsant effect [180] R-PIA (A1 receptor agonist)
4-aminopyridine-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform bursting duration 
Ado Receptor Agonists

3-nitropropionic acid-induced (intraperitoneal injection) seizures in mice
Anticonvulsant effect [266] Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Hypoxia-induced convulsions in mice Prolonged latency to convulsions [278] S-PIA (A1 receptor agonist)
Bicuculline-induced (rat prepiriform cortex) seizures Seizure protection [267] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Seizure prevention [95] Electroshock (ear-clip electrodes)-induced seizures in mice Increased electroconvulsive threshold [428] APNEA (A1/A3 receptor agonist)
Kindling (rat amygdala) model Enhanced anticonvulsive effect of antiepileptic drugs (e.g. carbamazepine and valproate) [296] Kindling (rat piriform cortex) model Proconvulsant effect [273, 276] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Seizure prevention [95] CGS 21680 (A2A receptor agonist)
Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats (animal model of human absence epilepsy)
Increased absence epileptic activity [302] CPCA (A2A receptor agonist)
Genetically epilepsy-prone rat (GEPR-9 strain; activation of seizures by auditory stimulus)
Seizure suppression [94] Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats Seizure reduction
Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Seizure prevention [95] 
Ado Receptor Antagonists
Kindling (rat piriform cortex, hippocampus, and amygdala) model Proconvulsant effect/no effect on seizures [273] [274] [275] [276] [277] 281] Mg 2+ -free artificial cerebrospinal fluid-evoked epileptiform activity Increased occurrence of seizures/enhanced duration and intensity of epileptiform activity [300] Mg 2+ -free condition-induced (rat hippocampal slices) epileptiform activity Induced persistent epileptiform discharges [303] CPT (A1 receptor antagonist) 4-aminopyridine-induced (rat hippocampal slices; Mg 2+ -free condition) epileptiform activity Enhanced discharge rate [140] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Proconvulsant effect
Pilocarpine-induced (intraperitoneal injection) seizures in rats Proconvulsant effect [180] Pilocarpine-induced (intraperitoneal injection) seizures in rats Reduced seizure occurrence [268] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Proconvulsant effect [95] SCH 58261 (A2A receptor antagonist)
Decreased absence epileptic activity [302] Audiogenic seizures (audiogenic-seizure-sensitive DBA/2 mice) Proconvulsant effect
Pilocarpine-induced (intraperitoneal injection) seizures in rats Proconvulsant effect [180] ( 
Direct (focal) Application of Urd
Pentylenetetrazole-induced (mice) seizures Anticonvulsant effect [350] Penicillin (frog cortex)-and penicillin plus pentylenetetrazole-induced seizures Anticonvulsant effect [351, 352] Bicuculline-induced seizures Anticonvulsant effect [354] Electroconvulsive model in rats Anticonvulsant effect [353] Kindling 
Direct (focal) Application of Ino
Quilonilic acid-induced (intracerebroventricular application) seizures in mice Seizure prevention [392] Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118, 390] Bicuculline-, pentylenetetrazole-and picrotoxin-induced (tail vein infusion and intraperitoneal injection) seizures in mice Increased seizure threshold [58] Ino Caffeine-induced seizures in mice Seizure reduction [391] 
Direct (focal) Application of Ado
Bicuculline-induced (rat hippocampus) seizures (focally injected Ado by infusion pump into hippocampus) Seizure prevention [117] Kainic acid-induced (intraperitoneal injection) seizures in rats (delivery of Ado by osmotic micropump into hippocampus) Seizure reduction [138] Lithium-pilocarpine-induced status epilepticus in rats (intraperitoneal application of Ado) Protective effect [216] Penicillin-induced (rat cortex) epileptiform activity (intracortical and intracerebroventricular application of Ado) Decreased epileptiform activity [120] Pentylenetetrazole-induced (intraperitoneal injection) seizures in rats Seizure protection [204] Pentylenetetrazole-induced (intraperitoneal injection) seizures in mice Increased seizure latency [118] Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats (animal model of human absence epilepsy) Increased absence epileptic activity [309] 4-aminopyridine-induced (rat hippocampal slices; Mg
2+
-free condition) epileptiform activity Decreased epileptiform activity [140] Bicuculline-induced (rat hippocampal slices) epileptiform activity Decreased epileptiform activity [168] Ado Mg 2+ -free condition-induced (human neocortical slices) epileptiform activity Decreased epileptiform activity [219] ( 
Modulation of Adenosine Levels and Epileptic Activity by Metabolic Enzymes
Regionally different Ado levels have been demonstrated in the human brain tissue [56] . The highest Ado concentrations (17.2-23.9 pmol/mg) were measured in the vestibular nuclei, cochlear nuclei and cerebellar cortex, while the lowest levels (1.4-2.4 pmol/mg) were demonstrated in the entorhinal cortex, locus coeruleus, habenula and zona incerta. Different cortical areas and limbic areas may be involved in epileptogenesis; the entorhinal cortex and hippocampus contained low to medium levels of Ado [56] . In addition, the highest Ado immunoreactivity was determined in the pyramidal cells of the hippocampus and granule cells of the dentate gyrus [122] . Approximately two-fold higher EC Ado levels were measured in the rat striatum (1.92 M) than in the hippocampus (0.93-0.95 M) and thalamus (0.95 M) [112, [123] [124] [125] [126] . In addition, uneven distributions of ADA activity and ADK activity, which may regulate Ado levels in the brain tissue, were revealed in the different brain areas. For example, the activity of ADA was intermediate to low in the hippocampus and intermediate to high in the cortical areas [31, [127] [128] [129] , and intermediate/low and very low levels of ADK activity were demonstrated in the cortex and hippocampus, respectively [31, 93, 130] . ADA activity decreased with age in the cortex and hippocampus [131] , which may induce an increase in Ado levels in elderly people. Indeed, concentrations of Ado exhibit age-dependent alterations in the human cerebral cortex (Ado concentration was higher in the elderly compared with middle-aged subjects) [57] and in all areas of the rat brain [132] . The highest level of SAH in the rat striatum and its modification by age has also been demonstrated [132, 133] , suggesting that SAHH activity is also unevenly distributed and may change with age in the brain.
Because of its lower K m value (ADK: 2.0 M; ADA: 17.0 M) [130] , ADK may be the key enzyme in Ado-level modulation [66, 134] ; thus, inhibition of ADK by ADK inhibitors (e.g., 5'-iodotubercidin, 5'-amino-5'-deoxyadenosine, 5'-deoxy-5-iodotubercidin ( Fig. 2A) and 4 Table 2) , which disrupts the metabolic clearance of Ado, induces an increase in the release of neuroprotective endogenous Ado [135] [136] [137] . An increased concentration of Ado enhances A 1 -mediated presynaptic inhibition in the hippocampus [136] and decreases the seizure activity in different models of epilepsy, such as the maximal electroshock (MES) seizure model, the kainic acid mouse and rat models, the Mg 2+ -free condition-induced epilepsy model and the bicuculline-induced seizure model [93, 134, 135, [138] [139] [140] [141] [142] [143] . The role of ADK in the modulation of epileptic activity was strengthened by Gouder et al. [93] in the epileptic hippocampus in which overexpressed ADK decreased the level of Ado [27, 144] and increased epileptic activity, whereas reduced ADK activity by the ADK inhibitor 5'-iodotubercidine decreased epileptic activity. Astrocytes play crucial role in ADK-dependent modulation of Ado levels [27, 135, 144, 145] because ADK expression was greatest in the astrocytes in the adult brain [146] , and the largest Ado release was measured from astrocytes (derived indirectly from degradation of astrocyte-released ATP and directly via nucleoside transporters) [29, [147] [148] [149] [150] . It has also been demonstrated that an increase of ADK expression under pathological conditions may cause an Ado deficiency, which may be considered a pathological hallmark of epilepsy [151] .
Epilepsy-precipitating effects, such as hypoxia, brain injury and inflammation, may induce A 2A receptor upregulation and an increase in Ado levels [152] . Rapid, acute downregulation of ADK expression has also been demonstrated after status epilepticus [93] , which may increase Ado levels transiently and decrease epileptic activity (initial seizure suppression) by an endogenous astrocyte-based antiseizure mechanism in the brain [27, 65] . However, a subsequent high, acute Ado concentration promotes glial activation and astrogliosis, one of the relevant features of the epileptic brain [153] , via stimulation of A 2A receptors [154, 155] . The expression of ADK by glial fibrillary acidic protein (GFAP)-positive astrocytes and the overexpression of ADK in parallel with the formation of astrogliosis has been observed [27, 65, 93, 156] . Additionally, although A 1 receptors may reduce astrogliosis [157] , expression of astrocytic A 1 receptors may be reduced by epileptogenesis [158] [159] [160] [161] . A 2A receptors are upregulated by high Ado levels [27] ; thus, the crucial role of Ado receptor expression in astrogliosis, the astrogliosisinduced increase in ADK activity and the disruption of Ado homeostasis have been suggested in epilepsy [151, 156, 162, 163] . It was concluded that (i) upregulation of ADK in chronic epilepsy mainly occurs in astrocytes via Adoreceptor-induced astrogliosis in the adult brain, (ii) high ADK activity in astrocytes results in a decrease of Ado concentration, which may induce chronic recurrent seizures, (iii) consequently, ADK may be the link between astrogliosis and neuronal dysfunction in epilepsy and (iv) astrogliosis and concomitant epileptic seizures may be prevented by Ado receptor modulation [65, 93, 164, 165] . In addition, it has been demonstrated that not only neurons but also astrocytes may contribute to the initiation, maintenance and spread of seizures and the astrocytic basis of seizure activity [144, 153, 166] . Clinically used antiepileptics, such as carbamazepine and vigabatrin, modulate the physiological processes in the brain and induce undesirable side effects [153, 167] , but astrocytes may be new therapeutic targets by which to reduce epileptic activity without suppressing the physiological neural activity.
Inhibition of both ADA and SAHH caused minimal effects on the Ado level under basal conditions and/or electrical stimulation [136, 137] , whereas the effect of ADA in the modulation of Ado concentration was more significant when the Ado level was increased by energy depletion [137] . In addition, ADA may induce burst firing [168] and increase the amplitudes of extracellularly recorded field potentials [169] in the hippocampus. The results are controversial regarding the effect of ADA inhibition on epileptic activity ( Table 2) . While increased epileptiform activity induced by both the ADA inhibitor 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) (Fig. 2B) was observed in a Mg 2+ -free artificial cerebrospinal fluid (ACSF)-induced model [141] , it has also been demonstrated that the ADA inhibitor BW534U87 decreased epileptic activity with minimal side effects in (i) a bicuculline-induced (rat hippocampal slices) epilepsy model, (ii) a seizure-prone epilepsylike (EL) mouse model, (iii) mouse threshold maximal electroshock seizures, (iv) rat supramaximal electroshock seizures, (v) a kindling rat model and (vi) a pentylenetetrazole (PTZ)-induced seizure model in mice [170, 171] . In bicuculline-and PTZ-induced seizures and in the genetically seizure-prone epilepsy-like mice, EHNA and/or 2'-deoxycoformycin were also effective against seizures [134, 143, 170, 171] .
It was observed that the application of the XO inhibitor allopurinol ( Table 2 ; Fig. 2C ) as adjunctive therapy is effective in seizure reduction [172] [173] [174] [175] [176] , in which allopurinol may act via a decrease of Ado and/or Guo degradation and an HGPRT-induced increase in Ado and Guo levels (Fig. 1 ) [30, 173] . Because of its relatively mild and negligible side effects, it was concluded that allopurinol may be an effective and safe adjuvant against intractable epilepsy [173] .
Increased e5'NT activity has been demonstrated in rat models of epilepsy induced by kainic acid, pentylenetetrazol and pilocarpine [177] [178] [179] [180] [181] and in patients with temporal lobe epilepsy [182] . In addition, the convulsant effect of e5'NT inhibition by , -methyleneadenosine-5'-diphosphate (APCP) has been demonstrated in rats [134] . These results suggest that enhanced activity of e5'NT after epileptic seizures may be an adaptive response, which increases the concentration of EC Ado and, as a consequence, the anti-epileptic effects via A 1 receptors; thus, modulation of e5'NT activity may be a new promising therapeutic tool against epilepsy.
The Specific Role of Adenosine in Inflammationinduced Epilepsy
Inciting effects (e.g., status epilepticus and infection) may induce glial and neuronal activation in affected brain areas [183] [184] [185] , which enhance the synthesis of proinflammatory cytokines (e.g., interleukin-1 (IL-1 ) and tumor necrosis factor (TNF-)) [185] [186] [187] [188] . Both IL-1 and TNFmay increase EC glutamate levels, which may induce hyperexcitability and seizures [153, 189] . A lipopolysaccharide (LPS)-induced increase in IL-1 may also result in cortical epileptiform discharges [190] , and the induction of IL-1 expression in astrocytes may have a role in the occurrence of absence seizures [191] . Because IL-1 and LPS increased ADK expression in astrocyte cultures [156] , the link between the LPS-induced increase in IL-1 and absence epileptic activity [192, 193] may be the decreased level of endogenous anticonvulsant Ado by ADK. In addition, LPS and IL-1 induced the release of ATP from hippocampal slices [194] , which may be metabolized extracellularly to Ado by ectonucleotidases [72, 75, 76] resulting in stimulation of A 2A receptors, which may downregulate the expression of A 1 receptors [195] and enhance Ado uptake by ENT transporters [196] . All of these effects may increase epileptic activity by decreased Ado-induced inhibition via A 1 receptors. An A 2A receptor antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-(4,3-c)1,2,4-triazolo(1,5-c)-pyrimidine (SCH 58261) prevented the LPS-induced increase in the IL-1 concentration in the hippocampus [152, 197] , whereas the A 2A receptor agonist (2-(4-(2-carboxyethyl)-phenylamino)-5'-N-ethylcarboxamido-adenosine (CGS 21680) decreased the release of TNF- [198] . Because glial cells contain Ado receptors [152, [199] [200] [201] the adenosinergic system may decrease inflammation-induced epilepsy via A 1 receptors. Adenosine reduces astrocyte proliferation via A 1 receptors, whereas A 2 receptors may induce it [201] ; thus, high A 1 receptor expression inhibits astrocyte proliferation, while A 2A receptor upregulation increases it [201] , which also suggests the link between the adenosinergic system and inflammationinduced epileptic activity. In addition, the anti-inflammatory action of ADK inhibitors has been demonstrated in different animal models [142, 202, 203] . Thus, ADK inhibitors may also have antiseizure activity. These results suggest that a therapeutic increase in Ado levels may decrease the risk of inflammation-induced epileptic seizures.
Fewer side effects were induced by ADK inhibitors than by intraperitoneally administered Ado-receptor-agonists, the effects of which included hypothermia, ataxia, cardiovascular side effects and sedation [118, 141, 204, 205] . Systemic application of ADK inhibitors as potential antiepileptic drugs is limited [86] by their cardiovascular and hypothermic side effects [141, 206] , their sedative effect and their CNS hemorrhaging effect [93] . In addition, Boison et al. [207] demonstrated lethal hepatic steatosis in ADK knockout mice.
Inhibition of Nucleoside Transporters
Nucleoside transporters are also unevenly distributed in the brain. Medium to high ENT1 levels have been demonstrated in the human brain areas (e.g., cerebral cortex, basal ganglia and thalamus), whereas these brain areas contained intermediate to low levels of ENT2. The hippocampus showed low ENT1 and ENT2 levels, but intermediate and high ENT3 and ENT4 expression have been demonstrated in the human brain [208] [209] [210] . High CNT2 and CNT3 activity have been demonstrated in the human hippocampus, whereas intermediate to low expression was revealed in the cerebral cortex [211, 212] .
Inhibitors of nucleoside transporters may increase the EC level of Ado, which may result in seizure suppression. Indeed, Ado uptake inhibitors, such as papaverine and/or dipyridamole, dilazep, hexobendine, soluflazine or NBTI (Fig. 2D) , (i) attenuated the amygdale-triggered (kindling) seizure activity [213] and the burst-firing of neurons of hippocampal slices in the bicuculline-induced epilepsy model [168] ; (ii) decreased PTZ-, pilocarpine-, bicuculline-and kainic-acid-induced seizures [134, 143, [214] [215] [216] and ketamine-induced epileptiform activity [217] ; (iii) had depressant effects on synaptic responses [169] ; (iv) inhibited epileptogenic population spikes (PS) [218] and (v) depressed epileptiform activity in a Mg 2+ -free medium [141, 219] ( Table 2) . The Ado uptake inhibitor, midazolam, depresses excitatory synaptic transmissions in the hippocampus [220] . In addition, Ado uptake inhibitors have less severe adverse effects compared to Ado receptor agonists [221, 222] . Some controversial results were described in relation to nucleoside transporter inhibition, e.g., papaverine may have pro-and anticonvulsant effects in different models [134, 213, 217, [223] [224] [225] . These results suggested that although Ado transport inhibitors may be effective antiepileptic drugs in several types of epilepsies, one has to be cautious regarding their applicability.
Adenosine Receptor Agonists and Antagonists
It has been revealed that A 1 receptors are expressed at medium to high density in the cerebral cortex, hippocampus and in some thalamic nuclei. High A 2A receptor density has been demonstrated in the basal ganglia, whereas medium to low levels were found in several brain areas, such as the cerebral cortex, thalamus and hippocampus [208, 226, 227] . In general, Ado levels in different brain areas show correlations with the distribution of Ado receptors. For example, low or moderate Ado concentrations in the human cerebral cortex and hippocampus correlate well with the medium to high A 1 receptor expression in these brain regions [30, 56] suggesting the involvement of Ado and its receptors in the modulation of hippocampal and cortical activity in pathological conditions such as epilepsy. It has also been supported by the demonstration of an epilepsy-induced decrease in A 1 receptor expression in chronic seizures [67, [158] [159] [160] 228] and adaptive changes in Ado receptors after seizures [111] . Activation of A 2B receptors by elevated Ado levels may induce the release of proinflammatory interleukin-6 (IL-6) from astrocytes leading to increased expression of A 1 receptors and their functions in the brain [229, 230] , which may explain (i) the increase of A 1 receptor expression after seizures parallel with increasing Ado level and (ii) the higher level of IL-6 in the brain areas (e.g., in the hippocampus and cortex) of epileptic patients and rats [186, [231] [232] [233] , which may have a protective effect against subsequent seizures [230] . In addition, an increase in A 1 receptor density has been demonstrated in the epileptic tissue, for example, in PTZ kindling mice and kainic-acid-treated rats, which may also be an adaptive/protective mechanism against hyperexcitability-induced seizures and convulsions [96, 230, [234] [235] [236] [237] [238] [239] .
Age-related decrease in A 1 receptor density was detected in both the cortex and hippocampus, whereas expression of A 2A receptors was increased in these brain areas with age [240] [241] [242] [243] [244] [245] . Changes in Ado receptor density may result in an imbalance between inhibitory (A 1 receptor) and excitatory (A 2A receptor) processes [242, [246] [247] [248] , which could shift the excitatory/inhibitory balance toward excitation in elderly people. In addition, A 2A receptor activation may inhibit A 1 receptors [98, 249, 250] . As a consequence, the increased risk of excitation and the consequent excitation-induced pathological processes may increase the sensitivity to epileptic seizures in elderly people [57, 251, 252] .
Activation of A 1 receptors by acute administration of their selective agonists, such as 2-chloro-N 6 -cyclopentyladenosine (CCPA) ( Table 3 ; Fig. 3A) , decreased the progression from self-terminating seizures to self-sustaining status epilepticus (SSSE) and decreased the severity of SSSE in a rat model of status epilepticus [68] . In addition, CCPA decreased the seizure activity in kainic-acid-induced epilepsy [92] , pilocarpine-induced seizures [253] and bicuculline-as well as PTZ-induced convulsions [254] [255] [256] . Both A 1 receptor agonists N 6 -cyclohexyl-adenosine (CHA) and N 6 -cyclopentyl-adenosine (CPA) (Table 3) suppressed the development of status epilepticus in electrical stimulation mod-els in rats [257] . An Ado analogue A 1 receptor agonist 2-chloroadenosine (2-CLA) ( Table 3) showed antiseizure effects in amygdaloid and hippocampal kindled rats [115, 116, 213, [258] [259] [260] , pilocarpine-induced seizures [216, 258, 261, 262] , electroshock-induced seizures [263] , Mg 2+ -free conditions [219, 264] , PTZ-induced seizures [118, 204, 255, 265 ], 3-nitropropionic-acid-induced seizures [266] , kainic-acidand 3-mercaptopropionic-acid-induced seizures [118] and bicuculline-induced seizures [168, 267] .
In addition, not only 2-CLA but also Ado receptor agonists 5'-(N-ethyl)carboxamidoadenosine (NECA; nonselective Ado receptor agonist) (Fig. 3B) [143, 168, 214, 256] and/or CPA [204, 235] , CHA (Fig. 3A) [118, 168, 216, 237] and D-, L-, R-and S-N 6 -(2-phenylisopropyl) adenosine (D-, L-, R-and S-PIA; A 1 agonists) ( Table 3 ; Fig. 3A) [118, 168, 180] were effective against bicuculline-and/or kainicacid-, pilocarpin-, 3-nitropropionic-acid-, 3-mercaptopropionicacid-and PTZ-induced seizures/epileptiform activity as well as 4-aminopyridine-induced epileptiform bursting activity [235, [265] [266] [267] [268] [269] [270] [271] and in the rat kindling model [119, [272] [273] [274] [275] [276] [277] . It has also been demonstrated that R-PIA prolonged the latency to convulsions in a hypoxia-induced model [278] and CPA delayed the time onset of clonic convulsions in aminophylline-induced seizures [279] . L-PIA blocked potassiuminduced epileptic activity [280] and prevented the spreading of penicillin-induced epileptic activity [106] .
The proconvulsant effect of the selective A 1 receptor antagonist, 8-cyclopentyl-1,3-dimethylxanthine (CPT) ( Table  3) , has also been demonstrated in kindled rats [273] [274] [275] [276] [277] 281] . The antiseizure role of A 1 receptors was recently strengthened because (i) A 1 receptor knockout mice showed spontaneous hippocampal seizures and high sensitivity to status epilepticus [282, 283] and (ii) seizure-activity-limiting effects of Ado (A 1 receptor)-induced attenuation of depolarizing GABA A receptor signaling has been demonstrated [284] . In addition, CCPA enhanced the antiseizure effect of carbamazepine in the mouse maximal electroshock seizure model [285] . It has also been demonstrated that a ketogenic (low-carbohydrate and high-fat) diet, which decreases the glucose level and increases the metabolism of ketones, may decrease seizure activity [286] [287] [288] by several hypothetic pathways, for example via enhanced levels of Ado and increased activation of A 1 receptors [121, [289] [290] [291] [292] . A ketogenic-diet-induced low glucose level may induce ATP release from neurons, and ATP may be metabolized subsequently to Ado, which hyperpolarizes the membrane by opening K + -channels and decreases the release of excitatory neurotransmitters via A 1 receptors. In addition, Ado attenuated the amplitudes of extracellularly recorded field potentials in the CA1 region of the hippocampus [169] , decreased the excitability of postsynaptic cells [293] and inhibited neurotransmitter release in the hippocampus [169, 293, 294] by increasing K + conductance [295] . The A 1 /A 3 receptor agonist, N 6 -2-(4-aminophenyl)ethyladenosine (APNEA) ( Table  3) , increased the seizure threshold in electroshock-induced seizures in mice and enhanced the anticonvulsive effect of antiepileptic drugs [296] . All of these results suggest that Ado may have an endogenous anticonvulsant/antiepileptic effect [70, 143, 168, 297] via mainly its A 1 receptors, but the antiseizure effect of A 2A receptors has also been suggested ( In a genetic-epilepsy-prone rat (generalized brain stem epilepsy in GEPR-9 strain), both CCPA and the A 2A receptor agonist, 5'-(N-cyclopropyl)-carboxamido-adenosine (CPCA) suppressed brainstem seizures [94] . CCPA, A 2A receptor agonists (CGS 21680 and 2-hexynyl-5'-N-ethylcarboxamidoadenosine (2-HE-NECA)), APNEA and NECA prevented the development of audiogenic seizures in audiogenicseizure-sensitive DBA/2 mice [95] . CCPA, 2HE-NECA and NECA decreased PTZ-induced seizures strengthening that both A 1 and A 2A receptor stimulation is involved in the suppression of seizures [95, 256] . Thus, the activation of not only A 1 receptors but also A 2A receptors may have antiepileptic potential in certain types of epilepsies [299] Fig. 3D) , and not only A 1 receptor antagonists (e.g., CPT) [300] (Table 3 ) but also A 2A receptor agonists (e.g., CGS 21680) (Fig. 3C) [302] and A 2A receptor antagonists (e.g., SCH 58261) [95] may also induce/enhance epileptic activity [140, [273] [274] [275] [276] 303] . PTZ-and pilocarpine-induced seizures were reduced in A 2A receptor knockout mice [304, 305] . In addition, for example, the A 2 selective ligand, 2-phenylaminoadenosine (CV-1808), had no seizuredecreasing effect [267] . Nevertheless, excessive stimulation of A 2A receptors in the brainstem may be involved in the pathomechanism of SUDEP (sudden unexpected death in epilepsy) [306, 307] . Rebola et al. [308] suggested that A 2A receptor antagonists may be more promising anticonvulsant drugs than A 1 agonists because they observed a long-term decrease and increase in A 1 and A 2A receptor density, respectively, after kindling-and kainic-acid-induced convulsion [308] . In addition, A 2A receptor antagonists may potentiate the neuroprotective effects of A 1 receptors [195] . Seizurepromoting modulatory effects on epileptic activity of A 3 receptors have also been suggested. For example, the A 3 receptor antagonist MRS 1191 decreased the epileptiform activity [300] (Table 3; Fig. 3E) .
The results described above suggest that purinergic mechanisms exhibit an ameliorating influence on various types of epilepsy via both antiseizure/antiepileptogenic effects. However, Ado and its receptors may have different roles in the modulation of different types of epilepsies. In addition, effects of Ado and Ado receptor agonists and antagonists may depend on the seizure model used ( Table 3) and place/mode of drug application. For example, CGS 21680 was proconvulsant and anticonvulsant in three different animal models [95, 273, 276, 302] . Adenosine decreased or increased epileptic activity in PTZ- [118, 204] , bicuculline- [117, 168] , pilocarpine- [216] , kainic-acid- [138] , Mg 2+ -free [140, 219] and penicillin-induced models [120] as well as in the animal model of human absence epilepsy [309] ( Table 4) , and focally applied Ado was more effective against penicillin-induced epileptiform activity than intracerebroventricularly injected Ado [120] . In addition, Ado receptor agonists and antagonists as well as nucleoside transport inhibitors may have different effects on seizures in the mature brain compared with the immature brain because of (i) the level and distribution of endogenous Ado, (ii) the affinity of Ado receptors for Ado, (iii) the distribution of Ado receptors and Ado transporters and (iv) the ratio of different types of Ado receptors and, consequently, the physiological and pathophysiological role of Ado in different brain areas may be changed by age [31, 57, [310] [311] [312] [313] . In addition, several other methodological circumstances, such as post mortem delay of brain tissue samples, age, gender, the species of experimental animals (subjects) and the type of solvent used, [30, 57, 314, 315] may modify the experimental results and effects of the applied drugs on epileptic seizures.
To obtain a complete antiepileptic profile of Ado and to reveal the exact modulatory effect of Ado and its analogs on different type of epilepsies, there is a need to investigate them in parallel in different in vivo and in vitro epilepsy models by similar methods (e.g., similar animal and slice models, as well as similar application mode/area of drugs, animal species and age of animals). In addition, Ado receptor (e.g., A 1 ) agents, at least fully selective agonists, (i) cause numerous side effects, (ii) have low blood-brain barrier permeability and short halflife and (iii) may induce adaptive changes (such as receptor downregulation); thus, their clinical potential may be limited [118, 141, 256, [316] [317] [318] [319] . However, partial agonists may prevent the desensitization [319] , and, thus, their application in epilepsy may be more promising.
Recently Developed Drugs Acting on the Adenosinergic System and Their Structure-activity Relationships
Advances in medicinal chemistry and structure-activity relationships produced a large number of novel drugs acting on the adenosinergic system, a promising drug target for a variety of disorders including epilepsy. The newly developed drugs may have advantages over the older drugs such as higher potency, better selectivity, enhanced bioavailability and less toxicity. Although most of these drugs have not been investigated for their effects in epilepsy models, they represent promising future directions in this research field.
Different classes of non-nucleoside molecules were developed as inhibitors of ADK, such as pteridine-, pyrazoloand pyrido-pyrimidine-based inhibitors of ADK [320, 321] . ABT-702 (Fig. 4A) , a pyridopyrimidine inhibitor demon- strated the highest potency among the orally available compounds [322] . Further structure-activity studies established that the 4-amino pyrimidine fragment and the aryl ring in the C(7) position are crucial pharmacophoric elements for pyridopyrimidines. However, although substances with higher in vitro potency have been produced, their in vivo efficacy remained suboptimal [323] . Coformycin and 2´-deoxycoformycin are outstandingly potent inhibitors of ADA. In fact, their almost irreversible blockage of ADA causes immunosuppressive side effects and toxicity. Nonetheless, crystallography revealed that the heterocyclic nitrogens do not form hydrogen bonds with the enzyme [324] . Instead, the heterocyclic ring interacted only with the Zn 2+ ion in the active site, while the sugar hydroxyl groups formed hydrogen bonds with amino acids Asp 19 and His 117. Therefore, it was possible to develop less potent analogues containing the imidazo [4,5- e][1,2,4]triazepine ring system (Fig. 4B) by removing the ribose moiety [325] . While coformycin and 2´-deoxycoformycin have been shown to act through so-called transition state inhibition of ADA, there are other modes of action, such as ground state inhibition of ADA. The structure of these drugs, including EHNA, resembles Ado, the endogenous substrate of the enzyme. Docking of EHNA to the ADA crystal structure revealed that the Ade NH 2 group formed a hydrogen bond with Asp 295 and 296, while the 2´-hydroxy group formed a hydrogen bond with the N hydrogen of His 17 and the S hydrogen of Cys 153 [326] . Modifications of the structure of EHNA using the 1-and 2-alkyl derivatives of the 4-aminopyrazolo [3,4-d] pyrimidine nucleus (Fig. 4C ) also led to potent inhibitors of ADA [326] . Structure-based drug design and metabolic considerations led to the development of additional non-nucleoside ADA inhibitors ( Fig. 4D ) with oral bioavailability [327] . Molecular modeling simulations suggested that the imidazolecarboxamide and the hydroxyl group of this compound are at the same binding positions as the Ade and hydroxyl group of EHNA, while the 2,3-dichlorophenyl ring stabilizes the compound metabolically [327] .
Another potential way of elevating the Ado level in the brain is by blocking SAHH. Following the crystallization of the enzyme, novel inhibitors were developed, including haloneplanocin A analogues [328] , among which fluoroneplanocin A was found to be the most potent (Fig. 4E) . Haloneplanocin A analogues exert their inhibition by being oxidized to their 3´-keto form by NAD + bound to SAHH, thereby maintaining the co-factor permanently in its reduced form NADH. However, the low bioavailability of these products led to further research to find SAHH inhibitors. Based on the ability of the Red Sea sponge product, ilimaquinone, to inhibit SAHH [329] , a new structural class of inhibitors of SAHH was developed (Fig. 4F) . Structure-activity studies on these compounds also revealed that the quinine moiety of ilimaquinone serves as a ribose mimic [329] .
ENTs are 11 transmembrane (TM) domain proteins with their N-termini in the cytoplasm and the C-termini in the EC space. Mutagenesis studies revealed that multiple TMs contribute to ENT function and that TMs 5 and 8 contain the largest number of operationally important residues [43] . Because the crystal structure of ENTs is not known, the structure of already available inhibitors was used for the rational design of novel inhibitors. Different classes of compounds were shown to inhibit ENTs present in the brain [330] .
Modifications of NBTI, including LUF5942, were found to be potent inhibitors with lowered polar surface area [331] . The most potent and selective inhibitor of ENT1 is nitrobenzylmercaptopurine riboside (NBMPR) (Fig. 5A) . Toxicity, selectivity and in vivo efficacy issues led to the development of some constrained analogues of NBMPR (Fig. 5B) as ENT1 inhibitors. The most suitable substitution position of the nitro group was explored by varying its position on the aromatic ring of the tetrahydroisoquinone moiety [332, 333] . In addition, novel fluorescent substrates have also been produced for probing transporter activity [334] .
Mammalian CNTs contain at least 13, and possibly 15, TMs. Permeant selectivity, drug interactions and cation coupling are primarily located in the C-terminal half of the protein, especially TMs 7, 8, 11 and 12 [43] . In contrast to ENTs, CNTs demonstrate some substrate specificity [43, 335] (Table  1) . CNT1 transports pyrimidine nucleosides and to some degree, Ado, CNT2 transports purine nucleosides and Urd, while CNT3 transports both classes with the ability to create a 10-fold higher concentration gradient due to 2:1 Na + -nucleoside coupling, suggesting that it might play a role under special circumstances [336] . There are fewer compounds available for the inhibition of concentrative nucleoside transporters than for equilibrative nucleoside transporters. The most commonly used non-specific inhibitor of CNTs is phloridzin (Fig. 5C) . Thus, recently developed non-nucleoside drugs for the inhibition of different classes of CNTs represent significant advances in the field by providing experimental tools for the involvement of these transporters in diseases including epilepsy [337] . The most potent selective inhibitor of CNT1 was a coumarin derivative (Fig. 5D) , while the most active compound, which was selective for CNT3, was 6-hydroxy-7-methoxyflavone (Fig. 5E) . In addition, selective CNT2 inhibitors (Fig. 5F ) have also been patented [338] . Structure-activity studies performed using the flavone structure pointed to significant differences between CNTs [337] . The flavone-binding site of CNT1 and CNT2 was quite stringent and that of CNT3 was tolerant in line with the lack of specificity of its nucleoside transport. Electrostatic interactions were dominant for all three CNTs, but hydrophobic interactions also played some role. In contrast, hydrogen-bonding interactions were important only for CNT2 and CNT3.
Drugs acting on Ado receptors have enormous potential in a variety of illness. Consequently, great efforts have been devoted to the medicinal chemistry of relevant compounds, which resulted in significant progress in the field [339] . In epilepsy, A 1 receptor agonists and A 2A receptor antagonists have the largest potential as therapeutic agents based on their inhibitory-excitatory activities and the abundance of these receptors in some brain regions. However, some data supports that antagonists acting on A 2B receptors and agonists of A 3 receptors may also have neuroprotective functions [340] . Furthermore, A 1 receptor antagonists and A 2A receptor agonists are also considered useful experimental tools. An issue in the development of drugs acting on Ado receptors is that the receptors demonstrate an unusually high species dependence. In particular, the affinity of drugs is often different in rodents and human [341] . Therefore, the results of animal experimentation have to be carefully interpreted. Another important point is the relatively fast desensitization of Ado receptors [342] , which argues for the use or partial agonists in in vivo experiments. The pharmacology of the A 1 receptor has recently been reviewed [343] . Most A 1 receptor agonists are N 6 -substituted Ado derivatives (e.g., selodenoson) (Fig. 6A) . Another beneficial effect of N 6 -substitution is the escape from degradation by ADA. Recently, non-nucleoside 2-amino-3,5-dicyanopyridine derivative A 1 receptor agonists (e.g., ca-padenoson) (Fig. 6B) were also developed. Furthermore, allosteric enhancers of the A 1 receptor were identified [344] , of which an example is shown (Fig. 6C) . Because the structure of the allosteric site is not known at the atomic level, subsequent structure-activity studies were performed, which demonstrated the importance of the 2-amino group of the 2-amino-3-aroyl-thiophene moiety. Furthermore, electronwithdrawing substituents on the benzoyl moiety and alkyl and aryl groups in the 4-and 5-positions of the thiophene ring also promoted allosteric enhancement activity [344] . Adenosine receptor antagonists were originally developed by the modification of the caffeine (Xn) structure. There are still such A 1 receptors antagonists produced (e.g., L-97-1) (Fig.  6D) . In general, modification of xanthines at the 8-position with aryl or cycloalkyl groups led to selectivity for the A 1 receptor. In addition, A 1 receptor antagonists with different structures, typically containing nonpurine heterocyclic core structures, have also been synthesized (e.g., FK-453) (Fig.  6E) . Substitution of Ado at the 2-position, especially with (thio)ethers, secondary amines and alkynes, resulted in compounds selective for the A 2A receptor.
A, ADK inhibitor
Some A 2A receptor agonists, including sonedenoson (Fig.  6F) , have also been clinically evaluated [345] . However, hypotensive side effects hinder their therapeutic applications. A 2A receptor antagonists (e.g., istradefylline) have been produced by the modification of xanthines at the 8-position with alkenes. In turn, very potent drugs, selective for the A 2A receptor were also developed by changing the heterocyclic structure (e.g., to triazolopyrimidine in vipadenant) (Fig.  6G) . Selective A 2B receptor antagonists have also been developed [346] . PSB-1115 (Fig. 6H) is water-soluble and therefore appropriate for in vivo studies, although its affinity and selectivity is suboptimal compared to some other A 2B receptor antagonists.
The structure-activity relationship of drugs acting on the A 3 receptor revealed that N 6 -benzyl and alkyl substituents favored binding to the A 3 receptor [347] . The prototypical A 3 receptor agonist is Cl-IB-MECA (Fig. 6I) , which has a 2000-fold affinity to the A 3 compared to the A 1 receptor. Cl-IB-MECA, the currently available A 3 receptor agonist, is a nucleoside derivative [341] .
Non-adenosine Nucleosides: Uridine, Guanosine and Inosine
Distribution of non-Ado nucleosides is also uneven in both the brain tissue and EC space [30, 56] . Highest Ino (101.5-161.5 pmol/mg) and/or Guo (19.5-26.1 pmol/mg) and Urd (43.9-55.1 pmol/mg) levels were measured in the caudate nucleus, substantia innominata, nucleus basalis, cochlear nuclei, temporal cortex, occipital cortex and medial geniculate body in the human brain. The lowest concentrations of Ino (29.8-39.5 pmol/mg) and/or Guo (4.1-5.1 pmol/mg) and Urd (15.7-16.7 pmol/mg) have been demonstrated in the ventral anterior nucleus, habenula, zona incerta, paraventricular nucleus, preoptic area, inferior colliculus and locus coeruleus. Medium non-Ado nucleoside levels were found in the hippocampus (Ino/Guo/Urd, pmol/mg: 53.7/12.7/38.3) and cortical areas (except temporal and occipital cortex) in the human brain. Extracellular levels of Ino and Guo were regionally different in rat brain areas. Their concentrations in the rat striatum, hippocampus and thalamus were 1.50-2.00, 0.42-1.37 and 0.52 M, respectively, for Ino and 0.50, 0.26 and 0.17 M, respectively, for Guo. Concentrations of Urd were similar in the rat thalamus (0.76 M) and hippocampus (0.71 M) [112, [123] [124] [125] [126] . Activity of PNP was intermediate to high in the cerebral cortex and thalamus [348] , whereas intermediate levels of GDA activity were demonstrated in the hippocampus and parietal cortex of the human brain. The thalamus showed a high level of GDA [349] . Higher Ino levels in elderly rather than middle-aged human samples and higher non-Ado nucleoside (Urd, Ino and Guo) levels in female samples compared with male samples have also been demonstrated in cortical samples [57] .
Nucleoside transporters may release/uptake not only Ado but also non-Ado nucleosides ( Table 1) ; thus, the antiepileptic effect of nucleoside transporter inhibition may also be in relation to decreased uptake of Ino and/or Guo and Urd. Indeed, the anticonvulsant effect of Urd has been demonstrated. Uridine reduced penicillin-, bicuculline-and PTZinduced seizures and was effective in electroconvulsive models ( Table 4 ) but did not protect against maximal electroshock-induced convulsions and 3-aminopyridine-induced seizures [112, [350] [351] [352] [353] [354] . However, it has been postulated that Urd may have a role in the initiation and termination of epileptic activity depending on its concentration [352] . More recently, Urd was found to be antiepileptogenic in hippocampal kindling models and in lithium-pilocarpine-induced status epilepticus in rats [63, 64] . In addition, an increased Urd level was detected in 3-aminopyridine-(3-AP)-induced epileptic seizures, which most likely inhibits neuronal activity [112] , and Urd reduces the firing rate of neurons in the hippocampus [59] . It has also been demonstrated by Dobolyi et al. [59] that Urd administration had no effect on the EC Ado concentration; thus, direct involvement of the adenosinergic system in an Urd-induced decrease in epileptic activity is not likely. However, indirect interaction between putative Urd receptors and Ado receptors has been demonstrated [83] as they may act together and result in anticonvulsant activity. Urd has been described to bind to a putative Urd receptor and the GABA A receptor [83, 84, 90, [354] [355] [356] suggesting that activation of both receptors by Urd may lead to a decrease in seizure susceptibility. As an increased Urd level may result in enhanced concentration of UTP [357] and UTP can change neuronal activity via its receptors [358] , an indirect inhibitory effect of Urd on epileptic activity via UTP/UDP [76, 359] receptors can be postulated. However, UTP was ineffective in 4-aminopyridine (4-AP)-induced epileptiform activity [140] . Uridine has already been tested in human studies [360] [361] [362] [363] [364] , and a decrease in seizure activity in response to Urd has been demonstrated in humans [363] [364] [365] . Uridine is also found in mother's milk and may be useful as a nutritional supplement during early postnatal development [366, 367] ; consequently, Urd is a well tolerable drug, which showed low toxicity [63, 64, 360, 361] . These results suggest that Urd and/or its analogues [83, 356] may be effective and safe drugs to treat epilepsy [31] .
Guanosine also has antiseizure effects in rodent epilepsy models, most likely via Guo-induced modulation of the glutamatergic system [60] [61] [62] [368] [369] [370] [371] . Guo may bind to its putative (uncloned) G-protein-coupled receptors in the brain [50, 51] . Guanosine levels increased after PTZ-induced seizures [372] , and Guo exerts a protective effect on quinolinic acid (QA)-induced seizures [60-62, 368, 373-377] (Table 4) and -dendrotoxin-induced seizures [371] likely by stimulation of astrocytic glutamate uptake [89, 373, 377, 378] . It has been demonstrated that GMP-and GTP-induced decreases in seizures may be related to their conversion to Guo [89, 368, 375] . Involvement of the adenosinergic system in antiepileptic effects of Guo has been suggested because Guo induces stimulation of Ado release from astrocytes [379] . In addition, Guo, released mainly from astrocytes, stimulates astrocyte proliferation possibly via increased level of Ado [380, 381] . However, (i) intraperitoneal administration of Ado enhanced [309] , (ii) an Ado receptor (A 1 and A 2 ) antagonist (theophylline) decreased [382] and (iii) activation of A 2A receptor triggered/maintained [302] the absence epileptic activity in WAG/Rij rats. In addition, the involvement of the adenosinergic system in the Guo-induced decrease in QA-induced seizure activity was excluded [62, 89] . All of these data support the idea that the Guo-induced increase in Ado levels in the brain may not decrease epileptic activity, at least not in relation to absence epilepsy and QA-induced seizure activity. However, the modulatory role of the adenosinergic system appears to be different in different types of epilepsies (e.g., theophylline enhanced the epileptiform activity induced by bicuculline) [168] ; thus, the additive antiepileptic effect of Guo and Ado in several epilepsy models (types) may not be fully explored. To summarize, Guo and/or its analogues may be potential antiepileptic drugs [62] because (i) Guo decreases glutamate concentration via upregulation of astrocytic glutamate uptake, consequently, (ii) Guo may shift the excitation/inhibition balance toward inhibition and (iii) Guo is a safe and well-tolerated drug for human use [62, 371, 383, 384] .
During bicuculline-, kainic-acid-, PTZ-and electroshockinduced seizures and 3-AP-induced epilepsy [112, 372, [385] [386] [387] [388] , as well as electrical or chemical depolarization [389] , the level of the Ado metabolites Ino and/or Hyp were also increased. It has been demonstrated that Ino (i) increased the latency to PTZ-induced seizures [118, 390] , (ii) antagonized caffeine-induced seizures [391] , (iii) has a role in the electroshock-induced increase in the threshold to PTZ-induced seizures [387] , (iv) had an anticonvulsant effect on QA-induced seizures [392] and (v) raised the threshold of seizures induced by PTZ, bicuculline and picrotoxin [58] (Table 4) . Interestingly, a synthetic Hyp derivative, AIT-082 (4-[[3-(1,6-dihydro-6-oxo-9-purin-9-yl)-1-oxopropyl]amino]benzoic acid), may exert its neuroprotective effect against kainic-acid-induced status epilepticus (longer latency, shorter duration) partly via Ino [393] . Early increases in Ino levels may play a role in the generation and propagation of seizures, but subsequent elevation of Ino and/or Hyp concentration may be responsible for seizure termination [386, 394] . Inosine and/or Hyp may be endogenous ligands of benzodiazepine receptors [395] [396] [397] [398] [399] and the picrotoxin binding site [400] in the nervous system. Picrotoxin, PTZ and bicuculline are inhibitors of GABA A receptors (which may produce seizures), and this receptor also contains a benzodiazepine binding site [401] . Thus, benzodiazepine receptor ligands, such as diazepam [8] and likely Ino, may enhance GABA-mediated inhibition and may decrease seizure activity. It has been concluded that antiseizure/anticonvulsant effect of endogenous Ino [58] may correlate with its interaction with inhibitory GABA A receptors (benzodiazepine receptors) [386, 390, 399, 402] . Recently, it was discussed that Ino may also bind to Ado receptors (A 1 , A 2A , A 3 ) [403] ; thus, the anticonvulsant effect of Ino may involve adenosinergic mechanisms as well. However, Ganzella et al. [392] demonstrated a decrease in seizures in response to Ino that was independent of the benzodiazepine and Ado receptors, which may involve Guo-induced astrocytic glutamate uptake [392] . Although (i) Ino binding site (binding to benzodiazepine receptors, to Ado receptors and/or to own specific Ino receptors, if any), (ii) interaction of Ino with other transmitter systems and (iii) modulators as well as exact signaling mechanism induced by Ino are not disclosed, these results suggest that Ino may also be a potential therapeutic agent in epilepsy.
NEW DEVELOPMENTS
Despite the ameliorating effect of ADK inhibition on epileptic seizures, side effects of systemic application of ADK inhibitors [93, 141] may limit their therapeutic use. In addition, systemic application of very high Ado doses may lead to astrogliosis-induced ADK expression and epileptic seizures; thus, focal application of Ado-releasing brain implants and in vivo gene therapies [67] may be a promising way to excite the anticonvulsant properties of Ado without severe side effects. In addition, a decrease in efficiency of the endogenous anticonvulsant Ado by efflux carriers via multidrug resistance-associated proteins is unlikely because of (i) the effective uptake mechanism of Ado via nucleoside transporters and (ii) the ADK-modulated Ado salvage mechanism, as described by Boison [65] . Direct administration of different drugs intraventricularly or intrathecally into the cerebrospinal fluid (CSF) would provide a solution for some of the problems regarding ADK inhibition. Administration of drugs via catheters has both advantages (e.g., the total amount of injected drugs reach the brain) and disadvantages (e.g., penetration of drugs from CSF into brain tissue may be limited) [404] .
To overcome the disadvantages concomitant with the direct infusion of drugs to CSF and to ensure the chronic delivery/long-term release of antiepileptic agents, Adoreleasing brain transplants (cells and polymers) were developed and applied. To enhance the Ado level and deliver it focally, intraventricular implantation of Ado-releasing (20-50 ng/day) synthetic biocompatible polymer (ethylene vinyl acetate copolymers) was applied in kindled rats ( Table 4 ) [114] , and this treatment decreased the seizure activity. Adenosine-releasing silk-base polymers may be a more suitable strategy for drug delivery than synthetic polymers because of their biocompatibility and slow biodegradation, thus avoiding the need for removal of the synthetic polymer which limits their clinical application [33, 67, 405, 406] . Wilz et al. [407] developed silk-based polymers that release 0-1000 ng/day and 0-819 ng/day of Ado in vivo and in vitro, respectively. Based on kindled rats, which were intrahippocampally implanted with silk-based polymers, they concluded that approximately 1000 ng/day Ado effectively decrease seizures, which could provide an opportunity for a safe decrease of epileptic seizures (Table 4 ) [407, 408] . These results suggest that focal synthetic-polymer-based and silk-based-polymer drug-delivery systems may release sufficient amounts of Ado to decrease epileptic activity. In addition, these systems may be safe without side effects.
Adenosine kinase may also be a therapeutic target for gene therapy [67, [409] [410] [411] [412] [413] [414] [415] [416] . Downregulation of ADK, thus increasing Ado levels, by adeno-associated virus 8 (AAV8)-mediated RNA interference (RNAi) in astrocytes (Table 4 ) [413, 414] and lentiviral RNAi-mediated downregulation of ADK in human mesenchymal stem cells [410] [411] [412] [413] were developed by which the seizure activity was reduced in mice. In an encapsulated Ado-biodelivery cell system, the cells are (i) genetically modified (result in ADK deficiency, IC accumulation of Ado and Ado release) to synthesize and release a therapeutic dose of Ado and (ii) encapsulated (enclosed in semi-permeable membrane). A semi-permeable membrane prevents, for example, graft-cell-host-cell interactions and graft rejection, but permits the delivery of Ado to the surrounding cells [67] . Encapsulated Ado-releasing (e.g., approximately 19 ng/h/10 5 cells) [417] cells (fibroblasts, myoblasts, baby hamster kidney cells and mouse embryonic stem cells) were implanted intraventricularly. Focal Ado delivery, in the nanomolar range, by Ado-releasing encapsulated implants (i) effectively decreased the epileptic activity in the kindling model (Table 4) [113, 150, [416] [417] [418] [419] [420] [421] , (ii) did not cause receptor desensitization or central and peripheral side effects, such as sedation and hypothermia resulting from the equilibration of Ado levels by nucleoside transporters [65, 419] , but (iii) usability may be restrained by limited long-term viability [67] . Implantation of Ado-releasing neuronal precursor cells into the rat hippocampus prior to kindling suppressed epileptogenesis (Table 4) [412, 422] . Intrahippocampal transplantation of Ado-releasing cells suppressed seizures in a kainic acid mouse model [165] . In addition, Ado accumulation, which may result in side effects, is precluded by EC metabolism of Ado by ecto-ADA [72, 75, 76] . Despite these results, implantation of Ado-releasing cells has advantages (e.g., there is no need to refill the system as with pumps and polymers) and disadvantages (e.g., the lack of control of drug release and the unknown longterm effects) [404] .
All of these promising preclinical results suggest that implantation of biodegradable Ado-releasing polymers and cells as well as gene therapy may be a safe and effective tool for the prevention and treatment of epileptogenesis and epilepsy via increasing Ado levels through the activation of mainly A 1 receptors. However, before clinical application of Ado augmentation therapy [67] new findings are needed, such as conclusive demonstration of (i) therapeutic index, (ii) long-term efficacy and (iii) usability in different types of epilepsies.
Although the binding and signaling mechanism of nonAdo nucleosides (Urd, Guo and Ino) as well as their exact effect on epileptic activity have not been established yet, the available data suggest an expansion of the adenosinergic/purinergic hypothesis in relation to epileptic activity [93, 423] ; therefore, we discussed that not only Ado but also endogenous Urd, Guo and Ino might have a crucial role in the modulation of the epileptic activity and sensitivity to epileptic seizures. Consequently, even if we have only sporadic data on the distribution and function of metabolic enzymes of Urd, Guo and Ino under different pathological conditions (e.g., epilepsy) in brain areas, we cannot exclude the possibility that their metabolic enzyme inhibitors are potential antiepileptic drugs, which increase the levels of non-Ado nucleosides. In addition, analogues of Ado-releasing implants, including Urd-, Guo-and Ino-releasing implants, may also be effective antiepileptic approaches. Silk fibroin encapsulation [406] may be a usable method to test this hypothesis. However, more detailed studies are necessary to reveal this novel possibility. In addition, the anti-inflammatory effects of not only Ado [197, 198, 201, 424] but also of Urd and Ino have been demonstrated [403, [424] [425] [426] ; thus, investigation of the effect of Urd and Ino on inflammationinduced exacerbation of epileptic activity [192, 193] may also be an interesting and promising novel drug discovery target in epilepsy research.
SUMMARY AND PERSPECTIVES
It has been demonstrated that impaired Ado-mediated inhibition may correlate with epilepsy. Adenosine and its metabolic enzymes, receptors and nucleoside transporters are unevenly distributed in the brain. In addition, Ado (i) is released under seizure activity, (ii) inhibits neuronal and seizure activity, (iii) increases seizure threshold, (iv) terminates seizures and (v) prevents the spreading of seizures via its receptors (mainly by A 1 receptors). These results suggest that Ado is an endogenous anticonvulsant/antiepileptogenic modulator, and purinergic mechanisms may be involved in the pathomechanism of the seizures.
Because seizure-induced increases in the endogenous anticonvulsant Ado levels result in decreased epileptic activity via activation of Ado receptors, Ado-based antiepileptic therapies are currently under development. Application of (i) Ado receptor agonists, (ii) Ado receptor antagonist, (iii) nucleoside transporter inhibitors, as well as (iv) the modulation of Ado metabolism (e.g., by ADK inhibitors) and (v) implantation of Ado-releasing cells/polymers may also be useful methods to therapeutically increase the level of the endogenous antiepileptic agent Ado and enhance Ado signaling. However, Ado receptor agonists and antagonists as well as ADK inhibitors may cause severe side effects, and Adoreleasing polymers have also several disadvantage. Conclusively, implantation of Ado-releasing stem cells/neuronal progenitor cells may be a more effective and attractive option to decrease epileptic activity, including in pharmacoresistant types of epilepsies, without the induction of severe side effects.
Because of the limited efficacy of antiepileptic therapy, approximately one third of epileptic patients are refractory to the available antiepileptic drugs, and the treatment of their epileptic syndromes remains unsolved. Thus, finding safe and well-tolerated drugs, such as Ado, Urd, Ino and Guo or other endogenous molecules (by which serious side effects may well be avoidable), or developing their analogues remains a high priority and a great need in epilepsy research. All available evidence suggests that the enhancement of endogenous antiepileptic mechanisms by increasing nucleoside levels in the brain may be a safe and effective therapeutic approach for the treatment of epilepsy. This review article presented literature data supporting the notion that not only Ado but also Urd, Ino and Guo, (i) may play important roles as endogenous anticonvulsant signaling/modulator molecules and (ii) may represent new pharmacological tools to treat different types of epilepsies. However, all drugs, which exert their effects on the purinome, affected receptors or changed nucleoside levels by acting on transporters and metabolic enzymes of the purinergic system [427] induced both ameliorating effects and pathological changes in the CNS. Thus, further studies are necessary (i) to reveal the exact effects of endogenous nucleosides and their analogues on the epileptic activity, (ii) to identify specific receptors of Urd, Ino and Guo (if any) and to disclose their signal transduction mechanisms, (iii) to explore the therapeutic indexes of nucleosides and their safety profiles (with emphasis on the relatively neglected nucleosides Urd, Ino and Guo as opposed to Ado), (iv) to test nucleoside-releasing implants (e.g., half-life, metabolism, storage and absorption of nucleosides) and (v) to investigate these promising therapeutic tools in both in vivo and in vitro models of different types of epilepsies under similar conditions before clinical application.
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